B-Cell chronic lymphocytic leukemia: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
mNo edit summary |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
In [[medicine]], '''B-Cell chronic lymphocytic leukemia''', also called '''chronic lymphocytic leukemia''' ('''CLL'''), is a "chronic [[leukemia]] characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting | {{subpages}} | ||
{{TOC|right}} | |||
In [[medicine]], '''B-Cell chronic lymphocytic leukemia''', also called '''chronic lymphocytic leukemia''' ('''CLL'''), is a "chronic [[leukemia]] characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominantly with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominantly with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease."<ref>{{MeSH}}</ref><ref name="pmid16983131">{{cite journal |author=Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE |title=Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia |journal=Ann. Intern. Med. |volume=145 |issue=6 |pages=435–47 |year=2006 |month=September |pmid=16983131 |doi= |url=http://www.annals.org/cgi/content/full/145/6/435 |issn=}}</ref><ref name="pmid15728813">{{cite journal |author=Chiorazzi N, Rai KR, Ferrarini M |title=Chronic lymphocytic leukemia |journal=N. Engl. J. Med. |volume=352 |issue=8 |pages=804–15 |year=2005 |month=February |pmid=15728813 |doi=10.1056/NEJMra041720 |url=http://content.nejm.org/cgi/content/full/352/8/804 |issn=}}</ref> | |||
==Prognosis== | ==Prognosis== | ||
{{Image|5-Year Relative Survival Rates By Year Dx By Leukemia type All Ages, All Races, Both Sexes 1975-2000.jpg| | {{Image|5-Year Relative Survival Rates By Year Dx By Leukemia type All Ages, All Races, Both Sexes 1975-2000.jpg|left|350px|5-Year Relative Survival Rates By Year Dx By Leukemia type All Ages, All Races, Both Sexes 1975-2000.}} | ||
===Staging information=== | ===Staging information=== | ||
{{PDQ-staging|http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page3}} | {{PDQ-staging|http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page3}} | ||
==Treatment== | ==Treatment== | ||
{{PDQ-treatment|http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page4}} | {{PDQ-treatment|http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page4}} | ||
As a primary [[antineoplastic agent]], [[fludarabine]] may be more effective than [[chlorambucil]].<ref name="pmid11114313">{{cite journal |author=Rai KR, Peterson BL, Appelbaum FR, ''et al'' |title=Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia |journal=N. Engl. J. Med. |volume=343 |issue=24 |pages=1750–7 |year=2000 |month=December |pmid=11114313 |doi= |url=http://content.nejm.org/cgi/content/full/343/24/1750 |issn=}}</ref> | As a primary [[antineoplastic agent]], [[fludarabine]] may be more effective than [[chlorambucil]].<ref name="pmid11114313">{{cite journal |author=Rai KR, Peterson BL, Appelbaum FR, ''et al'' |title=Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia |journal=N. Engl. J. Med. |volume=343 |issue=24 |pages=1750–7 |year=2000 |month=December |pmid=11114313 |doi= |url=http://content.nejm.org/cgi/content/full/343/24/1750 |issn=}}</ref> | ||
{| class="wikitable" | |||
|+ Treatment options for Stage I, II, III, and IV CLL<ref name="urlChronic Lymphocytic Leukemia Treatment - National Cancer Institute">{{cite web |url=http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page6 |title=Chronic Lymphocytic Leukemia Treatment - |author=Anonymous |authorlink= |coauthors= |date= |format= |work= |publisher=National Cancer Institute |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=2009-03-31}}</ref> | |||
! Regimen!! Effectiveness !! Adverse effects | |||
|- | |||
| Combination:<ref name="pmid15767647">{{cite journal |author=Wierda W, O'Brien S, Wen S, ''et al'' |title=Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia |journal=J. Clin. Oncol. |volume=23 |issue=18 |pages=4070–8 |year=2005 |month=June |pmid=15767647 |doi=10.1200/JCO.2005.12.516 |url=http://www.jco.org/cgi/pmidlookup?view=long&pmid=15767647 |issn= |accessdate=2009-03-31}}</ref><ref name="pmid18411418">{{cite journal |author=Tam CS, O'Brien S, Wierda W, ''et al'' |title=Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia |journal=Blood |volume=112 |issue=4 |pages=975–80 |year=2008 |month=August |pmid=18411418 |doi=10.1182/blood-2008-02-140582 |url= |issn= |accessdate=2009-03-31}}</ref><br/>• [[Fludarabine]]<br/>• [[Cyclophosphamide]]<br/>• [[Rituximab]] || Complete remission in 25% to 72%|| • Neutropenia<br/>• 10% rate of infection during first year<br/>• Rituximab induced fever (37%), chills (50%), hypotension (13%), nausea and vomiting | |||
|} | |||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 11:00, 15 July 2024
In medicine, B-Cell chronic lymphocytic leukemia, also called chronic lymphocytic leukemia (CLL), is a "chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominantly with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominantly with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease."[1][2][3]
Prognosis
Staging information
B-Cell chronic lymphocytic leukemia staging information from the National Cancer Institute's Physician Data Query
Treatment
B-Cell chronic lymphocytic leukemia treatment information from the National Cancer Institute's Physician Data Query
As a primary antineoplastic agent, fludarabine may be more effective than chlorambucil.[4]
| Regimen | Effectiveness | Adverse effects |
|---|---|---|
| Combination:[6][7] • Fludarabine • Cyclophosphamide • Rituximab |
Complete remission in 25% to 72% | • Neutropenia • 10% rate of infection during first year • Rituximab induced fever (37%), chills (50%), hypotension (13%), nausea and vomiting |
References
- ↑ Anonymous (2024), B-Cell chronic lymphocytic leukemia (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE (September 2006). "Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia". Ann. Intern. Med. 145 (6): 435–47. PMID 16983131. [e]
- ↑ Chiorazzi N, Rai KR, Ferrarini M (February 2005). "Chronic lymphocytic leukemia". N. Engl. J. Med. 352 (8): 804–15. DOI:10.1056/NEJMra041720. PMID 15728813. Research Blogging.
- ↑ Rai KR, Peterson BL, Appelbaum FR, et al (December 2000). "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia". N. Engl. J. Med. 343 (24): 1750–7. PMID 11114313. [e]
- ↑ Anonymous. Chronic Lymphocytic Leukemia Treatment -. National Cancer Institute. Retrieved on 2009-03-31.
- ↑ Wierda W, O'Brien S, Wen S, et al (June 2005). "Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia". J. Clin. Oncol. 23 (18): 4070–8. DOI:10.1200/JCO.2005.12.516. PMID 15767647. Retrieved on 2009-03-31. Research Blogging.
- ↑ Tam CS, O'Brien S, Wierda W, et al (August 2008). "Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia". Blood 112 (4): 975–80. DOI:10.1182/blood-2008-02-140582. PMID 18411418. Retrieved on 2009-03-31. Research Blogging.